NanoEcho
0,05 SEK
+6,44 %
Mindre end 1K følgere
NANECH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
+6,44 %
-29,96 %
-36,80 %
-14,28 %
-41,20 %
-66,80 %
-
-
-68,06 %
NanoEcho operates in the healthcare sector, with a primary focus on rectal cancer diagnostics. The company is currently in the clinical stage, developing a new diagnostic method to determine whether early rectal cancer has spread to nearby lymph nodes. The method aims to provide an accurate diagnosis and personalized treatment. NanoEcho was founded in 2013 and is headquartered in Lund.
Læs mereMarkedsværdi
33,68 mio. SEK
Aktieomsætning
52,65 t SEK
Omsætning
488 t
EBIT %
-3.030,53 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin
Omsætning t
EBIT-% (adj.)
EPS og udbytte
EPS (adj.)
Udbytte %
Finanskalender
30.4
2026
Delårsrapport Q1'26
28.5
2026
Generalforsamling '26
25.8
2026
Delårsrapport Q2'26